| Literature DB >> 24800224 |
Senka Imamovic Kumalic1, Bojana Pinter1.
Abstract
Infertility affects 50 to 80 million people worldwide. Male factor is a cause of infertility in almost half of cases, mainly due to oligoasthenoteratozoospermia (OAT). With common diagnostic methods no cause can be found in approximately 30% of cases of male infertility due to OAT and these are considered idiopathic. Reactive oxygen species (ROS) play an important role in male infertility and are proved to be higher in infertile men; antioxidants could oppose their effect. The aim of this paper was to review the literature on clinical trials in the period from year 2000 to year 2013 studying the effects of various types of antioxidant supplements on basic and other sperm parameters and pregnancy rates in subfertile males with idiopathic OAT. The majority of studies were randomized and placebo controlled and confirmed beneficial effect of antioxidants on at least one of the semen parameters; the biggest effect was determined on sperm motility. In many of these trials combinations of more antioxidants were assessed. The optimal dosages of one or more antioxidants were not defined. We concluded that antioxidants play an important role in protecting semen from ROS and can improve basic sperm parameters in case of idiopathic OAT.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24800224 PMCID: PMC3988936 DOI: 10.1155/2014/426951
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Study characteristics and the effect of oral antioxidants on basic and other semen parameters.
| Study/author | Year | Patients/test | Number of patients | Antioxidant/duration of th. | Significant improvement | Nonsignificant improvement | Negative effect |
|---|---|---|---|---|---|---|---|
| Wirleitner et al. [ | 2012 | OAT versus non-OAT, MSOME | 147 | Fertilovit Mplus/2–12 months | ↑ concentration and motility of sperm | Morphology | |
|
| |||||||
| Abad et al. [ | 2013 | AT/DFI, basic sperm parameters | 20 | L-Carnitine 1500 mg; vitamin C 60 mg; CoQ10 20 mg; vitamin E 10 mg; Zn 10 mg; vitamin B9 200 | DNA integrity ( | ||
|
| |||||||
| Safarinejad [ | 2011 | iOAT | 238 (analysis on 211) | SG: eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), 1.84 g per day versus PG/32 weeks | SG: ↑ of sperm cell total count (from 38.7 ± 8.7 × 106 to 61.7 ± 11.2 × 106, | In seminal plasma, both SOD-like and catalase-like activity were positively correlated with sperm count, sperm motility, and sperm morphology. | |
|
| |||||||
| Safarinejad [ | 2009 | iOAT/semen analyses, AR, immunobead test for antisperm antibody, and determination of resting levels of LH, FSH, prolactin, testosterone, and inhibin B | 212 | CoQ10 300 mg/26 weeks followed by a 30-week treatment-free phase | SG: ↑ in sperm density and motility (each | ||
|
| |||||||
| Safarinejad et al. [ | 2012 | iOAT/semen parameters, seminal plasma TAC, FSH, and inhibin B | 228 | CoQ10 200 mg/day/26 weeks | SG: ↑ in sperm density (28.7 ± 4.6 × 106/mL versus 16.8 ± 4.4 × 106/mL ( | ||
|
| |||||||
| Safarinejad [ | 2012 | iOAT/semen parameters and pregnancy rates | 287 | CoQ10 300 mg orally twice daily/12 months | Mean sperm conc., sperm progressive motility, and sperm with normal morphology improved by 113.7, 104.8, and 78.9%, respectively (all | The overall spontaneous pregnancy rate was 34.1% within a mean of 8.4 ± 4.7 months. | |
|
| |||||||
| Safarinejad [ | 2011 | iOAT/semen parameters, testosterone, LH, FSH, and inhibin B, seminal plasma SOD-like activity, and acrosome reaction | 254 | SG: PTX (pentoxifylline) 400 mg twice daily/4-week screening phase, a 24-week treatment phase, and a 12-week treatment-free period | SG after PTX: ↑ sperm conc. (mean value, from 26.4 ± 4.6 × 106/mL to 16.2 ± 3.4 × 106/mL), sperm motility (mean value, from 35.8 ± 4.2% to 26.4 ± 2.4%), and sperm with normal morphology (mean value, from 25.4 ± 4.3% to 17.4 ± 4.2%) | ||
|
| |||||||
| Ghanem et al. [ | 2010 | iOA/basic semen parameters, pregnancy incidence |
SG: 30 | Clomiphene citrate 25 mg/day + vit. E 400 mg/day/6 months | SG: sperm conc.: 10.2 × 106 ± 4.14 → 18 × 106 ± 15( | ||
|
| |||||||
|
M. R. Safarinejad and S. Safarinejad [ | 2009 | iOAT/serum T estradiol, FSH, LH, prolactin, inhibin B, Se, and N-acetyl-cysteine. Semen analysis, seminal plasma Se, and N-acetyl-cysteine. | 468 | SG 1: Se 200 | A strong correlation was observed between the sum of the Se and N-acetyl-cysteine concentrations, and mean sperm concentration ( | Se + N-ac-cy.: ↓ FSH, ↑ T, inhibin B | |
|
| |||||||
| Akmal et al. [ | 2006 | O/semen parameters | 13 | vitamin C 1 g twice daily/2 months | Mean sperm count: 14.3 ± 7.38 × 106 sperms/mL to 32.8 ± 10.3 × 106 sperms/mL ( | ||
|
| |||||||
| Shi et al. [ | 2004 | OA/seminal routine analysis | 34 | Xinxibao (Zn and Se tablets) three times a day/90 days + five tablets at a time for 90 days in succession | The sperm quality was improved 60 days and 90 days after treatment. 5 cases (14.7%) showed remarkable effect, 25 (73.5%) improved. | 4 cases (11.8%) did not respond. | |
|
| |||||||
| Suzuki et al. [ | 2003 | O and A versus normozoospermia/sperm parameters, serum hormones, and SOD activity in the serum and the seminal plasma + the testicular artery | SG: 47 | Sairei-to 9 g/day/3 months | SG: total sperm conc. (17.1 ± 20.0 to 28.7 ± 35.5 × 106/mL, | After th. serum hormones and SOD activity did not change significantly in either group. | |
|
| |||||||
|
Gupta and Kumar [ | 2002 | Idiopathic nonobstructive O/A/T spermia/semen analysis | 30 | Lycopene 2000 mcg, twice a day/3 months | 20 patients (66%): ↑sperm conc., 16 (53%) ↑ motility. The median change in concentration was 22 million/mL, motility 25%. Higher baseline concentrations (more than 5 million/mL) were associated with significant improvement and resulted in six spontaneous pregnancies in 26 patients (23%). | 14 patients (46%) ↑ in sperm morphology (median change 10%). Baseline sperm concentration less than 5 million/mL was associated with no significant improvement. | |
|
| |||||||
| Busetto et al. [ | 2012 | Idiopathic AT/basic sperm parameters | 114 (96 finished) | L-Carnitine 145 mg, acetyl-L-carnitine 64 mg, fructose 250 mg, citric acid 50 mg, Se 50 | ↑ Mean sperm progressive motility: 18.3 ± 3.8 to 42.1 ± 5.5, | Concentration and morphology | |
|
| |||||||
| Kumar et al. [ | 2011 | At least one parameter of OAT/basic semen parameters, ROS, TAC, and DFI (SCSA) | SG: 21 | herbal-mineral supplement Addyzoa/3 months | SG: total motility: 23.2 ± 17.3% → 33.4 ± 23.2% ( | ||
|
| |||||||
| Chen et al. [ | 2012 | O, A/sperm concentration and % of progressively motile sperm, the rate of clinical pregnancy | Oligosp: | Oligospermia: | Oligospermia: | Asthenosperm: after th, the number of cases evaluated as with moderate or marked improvement in the percentage of progressively motile sperm was 3 and 2 ( | |
|
| |||||||
| Wang et al. [ | 2010 | A/basic sperm parameters | 135 | Group A: L-carnitine 2 g/day + vitamin E | Group A: ↑ % of forward motile sperm (28.6% ± 9.2% to 45.4% ± 11.1%, | Group A: sperm density and the % of the sperm of normal morphology ( | |
|
| |||||||
| Piomboni et al. [ | 2008 | AT + leukocytosis/sperm parameters, DNA damage (acridine orange) | 51 (SG: 36 + CG: 15) | SG: beta-glucan 20 mg, fermented papaya 50 mg, lactoferrin 97 mg, vit. C 30 mg, and vit. E 5 mg, twice per day/3 months | SG: % of morphologically normal sperm (17.0 ± 5.2 to 29.8 ± 6.5) and total progressive motility (19.0 ± 7.8 to 34.8 ± 6.8), ↓ in leukocyte conc. (2.2 ± 0.9 to 0.9 ± 0.2), all | Structural sperm characteristics as well as chromatin integrity were also improved after treatment. | |
|
| |||||||
| Balercia et al. [ | 2004 | iA (WHO 1999)/basic sperm parameters, seminal plasma and sperm CoQ10, and phosphatidylcholine (PC) | 22 | CoQ10 200 mg 2x/day/6 months | CoQ10 sem. plasma (ng/mL: 42.0 ± 5.1 to 127.1 ± 1.9 ( | Sperm conc. and sperm morphology | |
|
| |||||||
|
Moslemi and Tavanbakhsh [ | 2011 | iAT/semen parameters and pregnancy rates | 690 (analysis on 525) | Se 200 | 52.6% (362 cases) total improvement in sperm motility, morphology, or both and 10.8% (75 cases) spontaneous pregnancy versus no treatment (95% confidence interval): 3.08 to 5.52; | No response to treatment occurred in 253 cases (36.6%) | |
|
| |||||||
| Keskes-Ammar et al. [ | 2003 | Infertile men/basic sperm parameters, MDA, and serum vitamin E level. | 54: | SG: vitamin E 400 mg + Se 225 | SG: ↓ in MDA concentrations and an ↑ of sperm motility | ||
|
| |||||||
| Cavallini et al. [ | 2012 | Idiopathic OAT/basic sperm parameters and aneuploidy (FISH) | 55 (analysis on 33: 22 responder—group 1 + 11 nonresponder—group 2) | L-carnitine 1 g given twice per day + acetyl-L-carnitine 500 mg given twice per day + one 30 mg cinnoxicam tablet every 4 days/3 months | Group 1 versus group 2: improvement in morphology and number of aneuploid spermatozoa ( | Numbers of oocytes fertilized and embryos transferred | |
|
| |||||||
| Roseff [ | 2002 | Subfertile/basic sperm parameters before and after capacitation and mannose receptor binding | 19 | Pycnogenol 200 mg daily orally/90 days | The mean sperm morphology following Ham's F-10 capacitation ↑ by 38% following th. ( | Baseline morphology ↑ after th. by 33% | The mean % change from baseline sperm count after th ↓ nonsignificantly by 10% |
|
| |||||||
| Song et al. [ | 2012 | Idiopathic OA/basic sperm parameters, DFI (SCSA) | SG: 24 | SG: vit. E + xuanju caps | SG versus CG: ↓ DFI after th.: 29.57 ± 12.19 versus 34.09 ± 10.32, | ||
|
| |||||||
| Ménézo et al. [ | 2007 | At least TWO pervious failures IVF or ICSI, DFI >15%/DFI and the degree of sperm decondensation (SCSA) | 58 | Vitamins C and E 400 mg each, | ↓DNA fragmentation: −9.1%, | ↑ in sperm decondensation | |
|
| |||||||
| Greco et al. [ | 2005 | TUNEL >15%/basic sperm parameters, TUNEL | 38 (26 OAT + 6 OT + 6 normal) | Vit. C 1 g + vit. E 1 g/2 months | TUNEL positive sperm: 24.0 ± 7.9 to 8.2 ± 4.3 ( | Sperm conc: 17.9 ± 16.3 to 18.3 ± 17.9 | |
|
| |||||||
| Greco et al. [ | 2005 | TUNEL >15%/basic sperm parameters, TUNEL | SG: 32 | Vit. C 1 g + vit. E 1 g/2 months | SG: ↓ fragm. DNA: 22.1 ± 7.7 → 9.1 ± 7.2 ( | PG: TUNEL: 22.4 ± 7.8 → 22.9 ± 7.9 | |
|
| |||||||
| Raigani et al. [ | 2013 | OAT/sperm quality, sperm mitochondrial function, sperm chromatin status, semen and blood folate, zinc, B12, TAC, and MDA concentr. | 83 | Folic acid 5 mg/day ± Zn sulphate 220 mg/day versus placebo/16 weeks | Sperm chromatin integrity (%) ↑ in group receiving only Zn sulphate treatment ( | Sperm conc. ↑ in group receiving the combined th. of folic acid and Zn sulphate and also in the group receiving only folic acid th.; ( | |
|
| |||||||
| Tremellen et al. [ | 2007 | Male factor infertility, TUNEL >25%/embryo quality, pregnancy and fertilization rate after IVF-ICSI | SG: 36 | Menevit (likopen, vit. C, vit. E, Zn, Se, folate, and garlic)/3 months | Pregnancy rate after ICSI in SG: 38.5%, versus PG: 16% ( | ||
|
| |||||||
| Safarinejad et al. [ | 2011 | iOAT/semen parameters and TAC of seminal plasma | 260 | Saffron 60 mg/day/26 weeks | No statistically significant improvements in either group in any of the studied semen parameters | ||
|
| |||||||
| Nadjarzadeh et al. [ | 2011 | iOAT/basic sperm parameters, TAC | 47 | CoQ10 200 mg/day/12 weeks versus placebo | SG: ↑ TAC ( | Semen parameters of CoQ10 group | |
|
| |||||||
| Comhaire et al. [ | 2000 | Infertile men/sperm characteristics, ROS, fatty acids of sperm membrane phospholipids, sperm oxidized DNA (8-OH-dG), and induced AR | 27 | N-acetyl-cysteine or vitamins A + E and essential fatty acids | ↓ ROS, ↑ AR | No improvement in sperm motility and morphology or ↓ of round cells and white blood cells in semen. Sperm concentration ↑ in oligozoosp. men (7.4 ± 1.3 to 12.5 ± 1.9 million/mL). | |
Legend: Addyzoa: Gokshura (Tribulus terrestris) 200 mg, Ashtavarga 200 mg, Guduchi (Tinospora cordifolia) 150 mg, Ashwagandha (Withania Somnifera) 150 mg, Amalaki (Emblica officinalis) 75 mg, Balamool (Sida cordifolia) 75 mg, Vridhadharu (Argyreia speciosa) 75 mg, Shatavari (Asparagus racemosus) 75 mg, Shwet musli (Chlorophytum arundinaceum) 150 mg, Shuddha kapikachchhu (Purified Mucuna pruriens) 150 mg, Varahikand (Tacca aspera) 30 mg, Chopchin (Smilax china) 30 mg, Vidarikand (Ipomoea digitata) 30 mg, Munjatak (Eulophia campestris) 15 mg, Purnachandrodaya rasa 45 mg, Suvarnavang 30 mg, Muktashukti bhasma 30 mg, Suvarnamakshik bhasma 30 mg, Shilajit shuddha 30 mg, Abhrak bhasma 15 mg, Makardhwaj rasa 15 mg, Rasa sindur 5 mg; AR: acrosome reaction; CG: control group; DDS: DNA degraded sperm; DFI: DNA fragmentation index; Fertilovit Mplus: L-citrulline (20.2 %), L-carnitine-L-tartrate, D-alpha-tocopheryl acetate, hydroxypropyl methylcellulose (capsule coating), acidifier tartaric acid, L-ascorbic acid (6.7%), parting compound silicon dioxide, calcium carbonate, lycopene, N-acetyl-L-cysteine, glutathione (reduced), corn starch, zinc oxide, coenzyme Q10, vegetable oil, shellac coating, pteroyl-L-glutamate, sodium selenite, coloring agent titanium dioxide (capsule), coloring agent orange yellow S (capsule); CoQ10: coencyme Q10, FISH: fluorescent in situ hybridization; FSH: follicle-stimulating hormone; ICSI: intracytoplasmic sperm injection; iOAT: idiopathic OAT; IVF: in vitro fertilization; LH: luteinizing hormone; MDA: malondialdehyde; MSOME: motile sperm organelle morphology examination; OAT: oligoasthenoteratozoospermia; PG: placebo group; ROS: reactive oxygen species; Sairei-to: a Chinese herbal drug; SCSA: sperm chromatin structure assay; Se: selenium; SG: study group; T: testosterone; TAC: total antioxidant capacity; TUNEL: TdT (terminal deoxyribonucleotidyl transferase)—mediated dUTP nick-end labeling; Xuanju: Formica fusca, Herba epimedii, Fructus cnidii, and Fructus lycii; Zn: zinc.